Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Comparison of Three Medications to Treat Diarrhea in Adults.

This study has been completed.
Information provided by (Responsible Party):
Johnson & Johnson Consumer and Personal Products Worldwide ( McNeil AB ) Identifier:
First received: December 9, 2008
Last updated: July 6, 2012
Last verified: July 2012
A comparison of three medications to treat diarrhea in adults.

Condition Intervention Phase
Drug: Loperamide/simeticone 2 mg/125 mg caplets
Drug: Loperamide/simeticone 2 mg/125 mg chewable tablets
Drug: Probiotic Saccharomyces boulardii 250 mg capsules
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Parallel Group Comparison of Loperamide/Simeticone Caplet, Loperamide/Simeticone Chewable Tablet (IMODIUM® PLUS) and a Probiotic (Saccharomyces Boulardii) in the Treatment of Acute Diarrhea in Adults

Resource links provided by NLM:

Further study details as provided by Johnson & Johnson Consumer and Personal Products Worldwide ( McNeil AB ):

Primary Outcome Measures:
  • Number of unformed stools [ Time Frame: 0-24 hours ]

Secondary Outcome Measures:
  • Number of unformed stools [ Time Frame: 0-12, 12-24, 24-36, 36-48 hours ]
  • Time to last unformed stool [ Time Frame: Throughout duration of the study ]
  • Time to complete relief of abdominal discomfort [ Time Frame: Throughout duration of the study ]
  • Time to complete relief of diarrhea [ Time Frame: Throughout duration of the study ]
  • Proportion of subjects with complete relief of diarrhea [ Time Frame: 4, 8, 12, 24 and 48 hours ]
  • Gas-related abdominal discomfort ratings - change from baseline at subsequent time points [ Time Frame: Throughout duration of the study ]
  • Proportions of subjects with complete well-being [ Time Frame: at 12, 24 and 48 hours. ]
  • Subject's evaluation of treatment effectiveness for overall illness relief, diarrhea relief and abdominal discomfort relief [ Time Frame: Throughout duration of the study ]
  • Number of loperamide/simeticone 2 mg/125 mg caplets or chewable tablets or probiotic (Saccharomyces boulardii) 250 mg capsules used during the study [ Time Frame: Throughout duration of the study ]
  • Frequency of complete well-being following diarrhea illness [ Time Frame: at 7 days follow up ]
  • Stool frequency [ Time Frame: at 7 days follow up ]
  • Frequency of diarrhea relapse [ Time Frame: at 7 days follow up ]
  • Safety Assessments will consist of monitoring and recording all non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs), their frequency, severity, seriousness, and relationship to the investigational product. [ Time Frame: throughout duration of the study (+ 30 days for spontaneously-reported SAEs) ]

Enrollment: 415
Study Start Date: November 2008
Study Completion Date: November 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Loperamide/simeticone Caplets
Drug (including placebo)
Drug: Loperamide/simeticone 2 mg/125 mg caplets
Oral, 2 caplets taken initially at investigator site followed by one caplet after each unformed stool, maximum 4 caplets in a 24 hour period for a maximum of 48 hours (per product label)
Other Name: Imodium® Plus Caplet
Active Comparator: Loperamide/simeticone Chewable Tablets
Drug (including placebo)
Drug: Loperamide/simeticone 2 mg/125 mg chewable tablets
Oral, 2 chewable tablets taken initially at the site followed by one chewable tablet after each unformed stool, maximum 4 chewable tablets in a 24 hour period for a maximum of 48 hours (per product label)
Other Name: Imodium® Plus Chewable tablet
Active Comparator: Probiotic Capsules
Drug (including placebo)
Drug: Probiotic Saccharomyces boulardii 250 mg capsules
Oral, 1 capsule twice a day, maximum 2 capsules in a 24 hour period for a maximum of 5 days (per product label)
Other Name: Perenterol® Forte 250mg capsules

Detailed Description:
This single (investigator) blind, randomized, 3-arm, parallel-group study design was selected to show non-inferiority of loperamide/simeticone caplets compared to chewable tablets in a heterogeneous subject population aiming at validity of results and reducing bias. The study will also compare the loperamide/simeticone combinations versus a probiotic (Saccharomyces boulardii) in the treatment of acute diarrhea in adults. Probiotics have been used for acute infectious diarrhea to reduce the duration and severity of the illness.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female at least 18 years of age
  • Acute diarrhea illness with symptoms onset within 48 hours of study entry
  • Minimum of 3 unformed stools in 24 hours before study entry
  • Most recent stool is unformed
  • Abdominal discomfort/wind (intensity mild to severe) within 4 hours of study entry
  • Women of childbearing potential must have a negative pregnancy test at screening
  • Willing to adhere to the prohibitions and restrictions specified in this protocol
  • Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study

Exclusion Criteria:

  • Requiring hospital admission, parenteral hydration or antibiotic therapy Axillary temperature >38.2°C or oral temperature >38.6°C
  • History or clinical evidence of gross blood or pus in stool in current illness
  • Signs or symptoms of orthostatic hypotension
  • Unable to take medication and fluids by mouth
  • History of chronic gastrointestinal disease, hepatic or renal insufficiency, or other significant medical condition that could be aggravated by untreated acute diarrhea
  • Immunodeficiency (e.g. those with acquired immunodeficiency syndrome [AIDS] or known human immunodeficiency virus [HIV] infection, or undergoing chemotherapy or radiotherapy)
  • Intake of antibiotics, oral antifungals, quinidine or ritonavir within 7 days, antidiarrhoeal, promotility drugs (e.g., metoclopramide, domperidone), antiflatulents (e.g., simeticone, activated charcoal) or probiotics or bismuth salts within 48 hours, or any analgesic within 6 hours prior to study entry Hypersensitivity to loperamide, yeast, or any component of study formulations
  • Pregnant or breast-feeding
  • Unable to comply with the protocol requirements and schedule
  • Any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study
  • Use of opiates (as 'recreational' drugs and as painkillers)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00807326

Manipal Goa Hospital
Goa, India, 403004
Vrundavan Hospital & Research Centre
Goa, India, 403527
North West Medical
San José del Cabo, Baja California Sur, Mexico, 22447
Dr. Maxwell´s Clinic
San Miguel de Allende, Guanuajuato, Mexico, 37700
Hospital Amerimed Puerto Vallarta
Puerto Vallarta, Jalisco, Mexico, 48300
Servicios Medicos de la Bahia
Puerto Vallarta, Jalisco, Mexico, 48300
Sponsors and Collaborators
McNeil AB
Study Director: Elisabeth Kruse, PhD McNeil AB
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: McNeil AB Identifier: NCT00807326     History of Changes
Other Study ID Numbers: LOPDIR4002
Study First Received: December 9, 2008
Last Updated: July 6, 2012

Keywords provided by Johnson & Johnson Consumer and Personal Products Worldwide ( McNeil AB ):

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Antifoaming Agents
Molecular Mechanisms of Pharmacological Action
Dermatologic Agents
Gastrointestinal Agents processed this record on May 25, 2017